| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/19/2010 | CA2235412C Pharmaceutical composition containing an activin or inhibin stimulator |
| 01/19/2010 | CA2183620C Sustained release composition |
| 01/19/2010 | CA2164517C Method of treating retained pulmonary secretions |
| 01/17/2010 | CA2653883A1 High fructan cereal plants |
| 01/15/2010 | CA2637977A1 Dosage form containing a statin |
| 01/14/2010 | WO2010006342A2 Compositions and methods for inhibiting expression of gsk-3 genes |
| 01/14/2010 | WO2010006315A2 Alpha-galactosyl ceramide analogs and their use as immunotherapies, adjuvants, and intiviral, antibacterial, and anticancer agents |
| 01/14/2010 | WO2010006306A1 Method of treating blepharitis |
| 01/14/2010 | WO2010006299A1 Analgesic agents |
| 01/14/2010 | WO2010006292A1 Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits |
| 01/14/2010 | WO2010006267A2 Cyclic tetrapeptides |
| 01/14/2010 | WO2010006261A1 Methods for inducing stem cell migration and specialization with ec-18 |
| 01/14/2010 | WO2010006249A1 Sustained release formulations of psychoactive drugs |
| 01/14/2010 | WO2010006238A2 Stimulus-responsive apta-chelamers |
| 01/14/2010 | WO2010006234A2 Anticancer oral formulation |
| 01/14/2010 | WO2010006231A1 Treating inflammation and related conditions with irindalone |
| 01/14/2010 | WO2010006225A1 Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway |
| 01/14/2010 | WO2010006192A1 Functional micelles for hard tissue targeted delivery of chemicals |
| 01/14/2010 | WO2010006191A1 4-phenoxymethylpiperidines as modulators of gpr119 activity |
| 01/14/2010 | WO2010006184A2 Small-molecule inhibitors of hif and angiogenesis |
| 01/14/2010 | WO2010006172A2 2-methylene-20(21)-dehydro-19-nor-vitamin d analogs |
| 01/14/2010 | WO2010006169A2 2-methylene-19, 26-dinor-(20s, 22e, 25r)-vitamin d analogs |
| 01/14/2010 | WO2010006162A2 2-methylene-(20e)-20(22)-dehydro-19-nor-vitamin d analogs |
| 01/14/2010 | WO2010006153A2 Topopyrones: dual topoisomerase inhibitors |
| 01/14/2010 | WO2010006143A2 Transdermal estrogen device and delivery |
| 01/14/2010 | WO2010006135A2 2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs |
| 01/14/2010 | WO2010006130A2 Pde-10 inhibitors |
| 01/14/2010 | WO2010006129A2 2-methylene-(22e)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin d analogs |
| 01/14/2010 | WO2010006125A2 2-methylene-19,26-dinor-(20r,22e,25r)-vitamin d analogs |
| 01/14/2010 | WO2010006123A2 19-nor-vitamin d analogs with 1,2-dihydrofuran ring |
| 01/14/2010 | WO2010006121A2 19-nor-vitamin d analogs with 3,2-dihydrofuran ring |
| 01/14/2010 | WO2010006115A1 Pharmaceutical compounds as cytotoxic agents and the use thereof |
| 01/14/2010 | WO2010006103A1 Method for enhancing cognition or inhibiting cognitive decline |
| 01/14/2010 | WO2010006096A1 Processes for the preparation of anti-viral compounds and compositions containing them |
| 01/14/2010 | WO2010006086A2 Kinase inhibitors and methods of use |
| 01/14/2010 | WO2010006085A1 Fatty acid acetylated salicylates and their uses |
| 01/14/2010 | WO2010006032A1 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof |
| 01/14/2010 | WO2010006026A2 Improving renal function with quercetin-containing compositions |
| 01/14/2010 | WO2010005989A1 Dermatological compositions with anti-aging and skin even-toning properties |
| 01/14/2010 | WO2010005986A1 Salts of hiv inhibitor compounds |
| 01/14/2010 | WO2010005980A1 Tacrolimus for improved treatment of transplant patients |
| 01/14/2010 | WO2010005961A2 Nutritive compositions and methods of using same |
| 01/14/2010 | WO2010005958A2 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| 01/14/2010 | WO2010005922A1 Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same |
| 01/14/2010 | WO2010005879A1 Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| 01/14/2010 | WO2010005876A2 Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| 01/14/2010 | WO2010005851A1 Combination therapy for treating iron disorders |
| 01/14/2010 | WO2010005850A1 Methods and compositions for modulating angiogenesis |
| 01/14/2010 | WO2010005836A2 Use of rifalazil to treat colonic disorders |
| 01/14/2010 | WO2010005807A2 Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats) |
| 01/14/2010 | WO2010005799A2 Novel acetates of 2-deoxy monosaccharides with anticancer activity |
| 01/14/2010 | WO2010005782A1 Sulfone compounds which modulate the cb2 receptor |
| 01/14/2010 | WO2010005766A1 Use of pharmaceutical compositions comprising a caspase inhibitor for treating interstitial lung diseases |
| 01/14/2010 | WO2010005765A1 Method of treatment and pharmaceutical compositions |
| 01/14/2010 | WO2010005741A1 Nanogels for cellular delivery of therapeutics |
| 01/14/2010 | WO2010005737A2 Artificial carbohydrate receptors and methods of use thereof |
| 01/14/2010 | WO2010005735A2 Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment |
| 01/14/2010 | WO2010005726A2 Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| 01/14/2010 | WO2010005725A2 Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| 01/14/2010 | WO2010005723A2 Drug loaded polymeric nanoparticles and methods of making and using same |
| 01/14/2010 | WO2010005721A2 Drug loaded polymeric nanoparticles and methods of making and using same |
| 01/14/2010 | WO2010005637A2 Electrostatically charged multi-acting nasal application, product, and method |
| 01/14/2010 | WO2010005585A2 4-aminoquinazoline prodrugs |
| 01/14/2010 | WO2010005581A1 Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad) |
| 01/14/2010 | WO2010005580A2 Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| 01/14/2010 | WO2010005572A2 Alpha-keto heterocycles as faah inhibitors |
| 01/14/2010 | WO2010005558A2 Pi3k isoform selective inhibitors |
| 01/14/2010 | WO2010005538A2 Silicone composition |
| 01/14/2010 | WO2010005534A2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells |
| 01/14/2010 | WO2010005528A2 Pyrrolopyridine carboxylic acid derivatives |
| 01/14/2010 | WO2010005520A2 2-alkyl-3-acylpyrazolo[1,5-a]pyridine derivatives |
| 01/14/2010 | WO2010005507A1 Topical regional neuro-affective therapy |
| 01/14/2010 | WO2010005480A2 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| 01/14/2010 | WO2010005465A1 L-carnitine and alkanoyl l-carnitine phytates and process for preparing the same |
| 01/14/2010 | WO2010005400A1 Opioid agonist compositions for pain management |
| 01/14/2010 | WO2010005385A1 2-amino-6-alkyl substituted pyridine derivatives useful as p2y12 inhibitors 308 |
| 01/14/2010 | WO2010005384A1 Ketone pyridine analogues and their use in the treatment of cardiovascular disorders |
| 01/14/2010 | WO2010005378A1 Antimicrobial composition |
| 01/14/2010 | WO2010005344A1 Nanosomal pharmaceutical form of a long acting preparation for treating hepatitis c (variants) |
| 01/14/2010 | WO2010005310A2 Complement antagonists and uses thereof |
| 01/14/2010 | WO2010005123A1 Composition for enhancing biosynthesis of hyaluronic acid or glycosaminoglycan comprising orotic acid, a salt thereof, or a derivative thereof |
| 01/14/2010 | WO2010005087A1 Amidine derivative |
| 01/14/2010 | WO2010005069A1 Immunity-inducing agent and method for detection of cancer |
| 01/14/2010 | WO2010005055A1 Oligonucleotide structure, and method for regulation of gene expression |
| 01/14/2010 | WO2010004982A1 Ameliorating or therapeutic agent for dyslipidemia |
| 01/14/2010 | WO2010004972A1 Nitrogen-containing aromatic heterocyclyl compound |
| 01/14/2010 | WO2010004916A1 Hypoglycemic agent, and food or beverage for prevention of diabetes or amelioration of condition of diabetes comprising same |
| 01/14/2010 | WO2010004837A1 Therapeutic agent for amyotrophic lateral sclerosis |
| 01/14/2010 | WO2010004816A1 Inhibitor of degranulation of mast cell |
| 01/14/2010 | WO2010004761A1 Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient |
| 01/14/2010 | WO2010004653A1 Eradicating agent and eradication method for helicobacter pylori |
| 01/14/2010 | WO2010004594A1 Ophthalmic compositions for treating pathologies of the posterior segment of the eye |
| 01/14/2010 | WO2010004579A2 Orally active curcuminoid compounds |
| 01/14/2010 | WO2010004577A1 Preparation of enantiomerically enriched gamma-nitro acid and pregabalin |
| 01/14/2010 | WO2010004573A1 Synergistic antimalarial pharmaceutical composition |
| 01/14/2010 | WO2010004525A1 Compositions containing a combination of propolis and a phenolic derivative and biological applications thereof |
| 01/14/2010 | WO2010004517A1 Triazole derivatives useful for the treatment of diseases |
| 01/14/2010 | WO2010004512A2 Dicabba-analogues of octreotide |
| 01/14/2010 | WO2010004507A1 Thiazolidine compounds as orexin receptor antagonists |
| 01/14/2010 | WO2010004394A1 9-substituted-b-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |